Biological Rare Disease

Ultomiris

Payments companies reported to CMS as associated with Ultomiris. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$11Massociated payments (2023-2025)
22,453clinicians with associated payments
2companies reporting

By year

2023 $2.8M
2024 $4.2M
2025 $3.9M

Payments reported as associated with Ultomiris, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $5.5M
Hematology & Oncology $868K
Nephrology (Internal Medicine) $803K
Neuromuscular Medicine (Psychiatry & Neurology) $599K
Family $415K
Medical Oncology $277K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Ultomiris

These are the largest totals companies reported as associated with Ultomiris. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Perry Shieh Los Angeles, CA Neurology (Psychiatry & Neurology) $219,443.93
Tuan Vu Tampa, FL Neurology (Psychiatry & Neurology) $215,581.98
Joshua Alpers Chattanooga, TN Neuromuscular Medicine (Psychiatry & Neurology) $173,659.81
Jeffrey Laurence New York, NY Hematology & Oncology $172,879.13
Ruth Fredericks Jackson, MS Neurology (Psychiatry & Neurology) $172,557.19
Bhupendra Khatri Milwaukee, WI Neurology (Psychiatry & Neurology) $170,794.21
Suraj Muley Phoenix, AZ Neurology (Psychiatry & Neurology) $155,838.11
Andrew Gordon Lake Barrington, IL Neurology (Psychiatry & Neurology) $152,123.39
Christopher Scheiner Dayton, OH Neurology (Psychiatry & Neurology) $128,748.31
Dennis Deruelle Knoxville, TN Internal Medicine $109,043.66

Prescribed Ultomiris?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.